Investors/Media

June 1, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 1, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will
May 3, 2022
SAN FRANCISCO --(BUSINESS WIRE)--May 3, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will
March 1, 2022
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 1, 2022-- Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will
Displaying 1 - 10 of 12